ClinicalTrials.gg
CompletedNCT00148902Updated Dec 6, 2017

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

A Phase 1 interventional study of lapatinib and docetaxel in Neoplasms, Breast, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Apr 2003, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
141st of 248
52 · median 68
Started
2003
with 23 others
Phase 1
23 of 264
none open now
Registered
66th of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 141st largest by enrollment of the 248 interventional ones that give a count, is one of 24 that started in 2003, is one of 23 in phase 1, and was the 66th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).

03

Conditions studied

  • Neoplasms, Breast

Keywords

  • tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Advanced solid tumors.
  • Able to swallow oral medication.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    All treated subjects

    All subjects received Lapatinib in Combination with Docetaxel (Taxotere)

    Drug: lapatinib · Drug: docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events (AEs) or serious AEs (SAEs)

    An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention will be categorized as SAE.

    Time frame: Up to 7 weeks in each cycle

  2. Number of subjects with abnormal change from Baseline in laboratory parameters

    Blood sample will be collected to evaluate laboratory parameters.

    Time frame: Baseline and up to 7 weeks in each cycle

  3. Number of subjects with Optimally Tolerated regimen

    Optimally Tolerated regimen is a dose regimen where 1 out of 6 subjects experiences a dose-limiting toxicity (DLT).

    Time frame: Up to 7 weeks in each cycle

Secondary outcomes

  1. Area under the plasma drug concentration curve (AUC) from 0 to infinity (AUC[0-inf]) of docetaxel alone (Pharmacokinetic [PK] cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  2. AUC within the dosing interval (AUC[0-tau]) of GW572016 alone (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.

  3. AUC (0-tau) of GW572016 when given in combination with docetaxel (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.

  4. AUC (0-tau) of GW572016 when given in combination with docetaxel (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion

  5. Maximum observed plasma drug concentration (Cmax) of docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  6. Cmax of GW572016 alone (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.

  7. Cmax of GW572016 when given in combination with docetaxel (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.

  8. Cmax of GW572016 when given in combination with docetaxel (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion

  9. Time to maximum observed plasma drug concentration (Tmax) of docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  10. Tmax of GW572016 alone (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.

  11. Tmax of GW572016 when given in combination with docetaxel (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.

  12. Tmax of GW572016 when given in combination with docetaxel (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion

  13. Concentration at the last measurable time point (Ctau) for GW572016 along (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.

  14. Time to first measurable plasma drug concentration (Tlag) for GW572016 along (PK cohort 2)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.

  15. AUC from time zero to time of last measurable concentration (AUClast) for docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  16. Clearance (CL) for docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  17. Volume of distribution at steady state (Vss) for docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  18. Elimination half-life (Thalf) for docetaxel alone (PK cohort 1)

    Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.

    Time frame: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.

  19. Number of subjects with complete response

    Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.

    Time frame: Week 3 of every third cycle

  20. Number of subjects with partial response

    Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.

    Time frame: Week 3 of every third cycle

  21. Number of subjects with stable disease

    Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.

    Time frame: Week 3 of every third cycle

  22. Number of subjects with progressive disease

    Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.

    Time frame: Week 3 of every third cycle

07

Study locations

2 sites
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2003 to primary completion in Jan 2006, 32 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 32 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
StartActual
Apr 28, 2003
Primary completionActual
Jan 21, 2006
CompletionActual
Jan 21, 2006
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00148902
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Apr 28, 2003
Primary completion
Jan 21, 2006
Completion
Jan 21, 2006
Last update
Dec 6, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion